By Emily Marson, L.Ac. | Aphrodite Fertility Acupuncture, San Diego

No peptide is FDA-approved for endometriosis right now, and none is proven safe to self-inject while you are trying to conceive. One candidate, ENDO-205, entered human trials in March 2026. A handful of others look promising in animal and lab-dish studies. The rest, the compounds sold online as a fertility fix, are unregulated and untested in pregnancy. Patients bring up BPC-157 in consults. Reddit threads swap thymosin protocols for pelvic pain. A friend swears semaglutide fixed her cycle. Some of that traces back to real science. Some of it is marketing dressed up as research. Here is what is actually happening with peptides and endometriosis, and what it means if you are trying to get pregnant while managing this disease.

Why does endometriosis need a different kind of treatment?

Endometriosis affects an estimated 190 million women worldwide (Drug Discovery News), and treatment has barely moved in decades. Suppress the hormones. Cut out the tissue. Repeat when it comes back. Neither option touches the immune dysfunction driving the disease, which is a large part of why symptoms return after excision surgery.

The fertility problem and the pain problem are separate, and that distinction matters. Inflammatory cytokines in the peritoneal fluid interfere with egg quality and embryo development. Macrophages in the pelvis disrupt how sperm and egg function together. During the implantation window, inflammation suppresses the exact genes and proteins the uterine lining needs to let an embryo attach. That is why some women with mild endometriosis still cannot conceive. It is not always scar tissue blocking a tube. It is a pelvic environment inflamed at the cellular level.

Peptide research is interesting for one reason. It aims at that inflammation directly, instead of shutting down hormones or cutting tissue out.

Which peptide is actually in human trials?

In March 2026 the FDA cleared an Investigational New Drug application for ENDO-205, developed by EndoCyclic Therapeutics (Contemporary OB/GYN, Drug Discovery News). It is the first non-hormonal precision peptide designed to target and eliminate endometriotic lesions rather than starve them of hormones. The company is starting phase 1 trials in reproductive-age women.

Pay attention to this one for a specific reason. It is the first disease-modifying endometriosis drug to reach human testing that does not work by shutting down the ovaries. If it holds up through trials, it could be the first real option in a category that has not seen genuine innovation in years. It is not available now. It will not be available for years. It signals where serious pharmaceutical research is heading, and that matters if you are tracking the field.

How do GLP-1 agonists connect to endometriosis?

Semaglutide and its relatives were built for diabetes and weight management, not fertility. Researchers are now looking at their anti-inflammatory effect on endometrial tissue specifically. Early studies show GLP-1 agonists upregulate progesterone receptors and calm inflammatory signaling in endometrial cells (Dr. Seckin, citing Hagemann et al., Cancers, 2025). That is relevant because progesterone resistance is one of the core mechanisms keeping lesions active.

None of this is established endometriosis treatment. The research so far centers on endometrial hyperplasia and cancer prevention more than on endometriosis or fertility outcomes. It is a real thread researchers are pulling on, and it shows how the thinking has shifted. Inflammation, not just hormones, is now the target.

Which research-stage peptides keep getting attention?

A handful of peptides show up constantly in fertility and endometriosis forums. Here is the honest state of the evidence on each.

Thymosin beta-4

Preclinical data, including work out of the University of Edinburgh, shows thymosin beta-4 reduces the fibrosis pathway responsible for the adhesions that cause chronic pelvic pain (Real Peptides). It also appears to shift inflammatory macrophages toward a tissue-repair state. This is animal and lab-dish research. It has not been tested in human endometriosis patients.

BPC-157

Recommended constantly online for tissue repair and gut health, and by extension reproductive tissue (Inovi Fertility). The human safety data is thin, and it is not approved or regulated for any use. Anyone considering it is self-administering an unregulated compound with no controlled human safety studies behind it for this purpose.

LL-37

A naturally occurring antimicrobial peptide already present in the body, upregulated abnormally in endometriosis lesions (Peptides Lab UK). Its role is double-edged in early research: helpful for implantation at the right concentration, potentially harmful when overexpressed in ectopic tissue. That makes it a fascinating research target and a terrible candidate for casual supplementation, because more is not better here.

CXCR4-targeted peptide nanoparticles

Being tested in rat models to block the blood vessel growth that lets lesions establish and spread (Egorova et al., International Journal of Molecular Sciences, 2025). This is early delivery-system research, years from human use. It points to where treatment design is heading: peptides that carry a payload straight to lesion tissue rather than circulating through the whole body.

What is the blunt truth about buying peptides online?

Most peptides sold online as research chemicals for fertility or endometriosis are not regulated, not tested for purity, and not studied in pregnant or trying-to-conceive populations. If you are actively trying to conceive, this is not the moment to experiment with unregulated compounds on your own. The distance between promising in a petri dish and safe to inject while your body is building a placenta is enormous, and it is a gap most sellers skip past.

If a peptide interests you, bring it to your reproductive endocrinologist. Ask specifically what human data exists, not just what preclinical data exists. Those are two different conversations.

Where does acupuncture fit into this picture?

Here is the connection worth making. The mechanisms this wave of peptide research keeps circling back to, inflammatory cytokines, macrophage activity, pelvic blood flow, the implantation window, are the same systems acupuncture has targeted for fertility support for years. We are not claiming acupuncture works through the same molecular pathway as ENDO-205, or that it replaces it. It does not, and it does not need to.

What we do at Aphrodite is support the terrain these treatments operate in. Lower systemic inflammation. Improve pelvic blood flow. Steady the nervous system through a diagnosis that is exhausting to live with. As precision peptide therapies move through trials over the next several years, acupuncture stays useful as a complement, not a competitor, to whatever pharmaceutical options eventually reach patients.

Frequently asked questions

Are there any FDA-approved peptides for endometriosis right now? No. ENDO-205 is the closest, and it only received IND clearance in March 2026 to begin phase 1 human trials. No peptide is currently approved specifically for endometriosis.

Is BPC-157 safe to use for endometriosis or fertility support? There is no controlled human safety data for this use, and it is not regulated. Anyone considering it should discuss it with a reproductive endocrinologist first, not a peptide vendor.

Can GLP-1 drugs like semaglutide help with endometriosis? The research connecting GLP-1 agonists to endometrial inflammation and progesterone receptor activity is real but early, and it is not currently studied or approved as an endometriosis treatment.

When might peptide therapies for endometriosis become available? If ENDO-205 or similar candidates succeed through phase 1, 2, and 3 trials, realistic timelines for approval and availability run several years out at minimum.

Does acupuncture treat endometriosis the same way these peptides do? No. Acupuncture does not target lesion tissue directly. It supports the inflammatory and circulatory systems that affect symptoms and fertility outcomes, a different mechanism working toward related goals.

Ready to find your answers?

If you are managing endometriosis and trying to conceive in San Diego, the useful next step is a plan built around your pelvic environment, not the latest forum thread. Book a new patient visit at https://aphrodite.janeapp.com/ or call 858.333.7688. You can also read our acupuncture approach to endometriosis and fertility and more on immune-driven implantation failure.

Emily Marson, L.Ac., is the founder of Aphrodite Fertility Acupuncture in San Diego. She has spent more than eight years helping women conceive and partners with every major San Diego fertility clinic. Located at 2970 Fifth Ave, Suite 320, San Diego, CA 92103.

Sources

1. EndoCyclic Therapeutics announces FDA clearance of IND application for ENDO-205. Contemporary OB/GYN, March 2026. contemporaryobgyn.net
2. Foster, B. Is this the first disease-modifying treatment for endometriosis? Drug Discovery News, May 2026. drugdiscoverynews.com
3. GLP-1 in Endometriosis: What We Know So Far, citing Hagemann AR, et al., Cancers (Basel), 2025, and related reviews. drseckin.com
4. Egorova A, Freund S, Krylova I, Kislova A, Kiselev A. Anti-Angiogenic RNAi-Based Treatment of Endometriosis in a Rat Model Using CXCR4-Targeted Peptide Nanoparticles. International Journal of Molecular Sciences, October 2025. PMC
5. Best Peptides for Endometriosis Research UK 2026. Peptides Lab UK, May 2026. peptideslabuk.com
6. Best Peptides for Endometriosis. Real Peptides, May 2026. realpeptides.co
7. Regenerative Peptides for Reproductive Tissue Repair and Delivery Platforms. Inovi Fertility, November 2025. inovifertility.com

Note: several sources above are peptide vendor or industry sites rather than peer-reviewed journals. They are included because they aggregate the current preclinical literature clearly. Verify the underlying claims against the primary studies they cite before treating any of it as clinical fact.